Trial Profile
Single-arm,Multi-center,Phase II Clinical Trial of the Efficacy and Safety of AC0010 in the Treatment of EGFR T790M Mutation-positive Patients With Advanded NSCLC
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Avitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Hangzhou ACEA Pharmaceutical Research
- 31 Jan 2019 Planned primary completion date changed from 17 Dec 2018 to 17 Jun 2019.
- 06 Oct 2017 New trial record